<DOC>
	<DOCNO>NCT00513630</DOCNO>
	<brief_summary>The purpose study explore recurrence risk cardiovascular event patient type 2 diabetes mellitus coronary heart disease different antidiabetic drug therapy ( glipizide metformin ) use double-blind , randomize , parallel control prospective study The end point study : 1. follow 3yr 2. recurrence cardiovascular event 3. death cause reason stroke , uremia , blindness amputation</brief_summary>
	<brief_title>Study Prognosis Effect Anti-diabetic Drugs Type-2 Diabetes Mellitus With Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<mesh_term>Glipizide</mesh_term>
	<criteria>Coronary heart disease Type 2 diabetes Severe organ dysfunction , psychopathy , infection , neutropenia Congenital heart disease , rheumatic heart disease , severe arrhythmia , myocardiopathy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>